All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

J&J’s Darzalex gains first FDA approval in smouldering multiple myeloma

Johnson & Johnson’s (J&J) blockbuster oncology asset, Darzalex Faspro (daratumumab and hyaluronidase-fihj) has gained US approval in smouldering multiple myeloma…
Agentic, deeply embedded AI constitutes the “next wave” of tech

Artificial intelligence (AI) has become a key buzzword in the pharmaceutical industry, with most, if not all, companies looking to…
Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war

Pfizer has followed through on its threats, filing a lawsuit against both Metsera and Novo Nordisk during a M&A bidding…
FDA looks to simplify biosimilar development with new draft guidance

The US Food and Drug Administration (FDA) has debuted new draft guidance that aims to streamline and expedite the biosimilar…
GSK forges pact with Empirico for respiratory siRNA in $745m deal

GSK has signed a licensing deal with Empirico for its respiratory disease-focused silent interfering RNA (siRNA), EMP-012. The UK-based big…

Organon CEO stands down amid contraceptive sales malpractice probe

Organon CEO Kevin Ali has stepped down from his leading position at the company, following its board’s discovery of sales…
UK regulators seize illegal weight loss drugs amid global pricing shake-up

UK drug regulators have shut down an illicit manufacturing facility producing counterfeit glucagon-like peptide-1 receptor agonist (GLP1-RA) medications in the…
Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls

Takeda and Innovent Biologics have signed a deal worth up to $11.4bn following its bid to focus on bispecifics and…
Novo Nordisk sees board shakeup amid member exodus

Novo Nordisk has announced that seven members of its board of directors will stand down from their roles. This includes…
ESMO 2025: Merck KGaA’s ADC leapfrogs to Phase III in colorectal cancer

Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown promising efficacy during an early-stage trial in heavily pre-treated colorectal…